National Academies Press: OpenBook

Drug Repurposing and Repositioning: Workshop Summary (2014)

Chapter: Appendix C: Statement of Task

« Previous: Appendix B: Speaker Biographical Sketches
Suggested Citation:"Appendix C: Statement of Task." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

C

Statement of Task

An ad hoc planning committee will plan and conduct a public workshop to examine and discuss genomics-based approaches to repurposing existing or developing therapeutics. The goal of the workshop will be to assess the current landscape of drug repurposing activities in industry, academia, and government; examine enabling tools and technology; evaluate the business models and economic incentives; and advance discussions among a broad array of stakeholders that may include government officials, pharmaceutical company representatives, academic researchers, regulators, funders, and patients. The planning committee will develop the workshop agenda, select and invite speakers and discussants, and moderate the discussions. An individually authored summary of the workshop will be prepared by a designated rapporteur in accordance with institutional policy and procedures.

Suggested Citation:"Appendix C: Statement of Task." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×

This page intentionally left blank.

Suggested Citation:"Appendix C: Statement of Task." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 89
Suggested Citation:"Appendix C: Statement of Task." Institute of Medicine. 2014. Drug Repurposing and Repositioning: Workshop Summary. Washington, DC: The National Academies Press. doi: 10.17226/18731.
×
Page 90
Next: Appendix D: Registered Attendees »
Drug Repurposing and Repositioning: Workshop Summary Get This Book
×
Buy Paperback | $38.00 Buy Ebook | $30.99
MyNAP members save 10% online.
Login or Register to save!
Download Free PDF

Drug development can be time-consuming and expensive. Recent estimates suggest that, on average, it takes 10 years and at least $1 billion to bring a drug to market. Given the time and expense of developing drugs de novo, pharmaceutical companies have become increasingly interested in finding new uses for existing drugs - a process referred to as drug repurposing or repositioning.

Historically, drug repurposing has been largely an unintentional, serendipitous process that took place when a drug was found to have an offtarget effect or a previously unrecognized on-target effect that could be used for identifying a new indication. Perhaps the most recognizable example of such a successful repositioning effort is sildenafil. Originally developed as an anti-hypertensive, sildenafil, marketed as Viagra and under other trade names, has been repurposed for the treatment of erectile dysfunction and pulmonary arterial hypertension. Viagra generated more than $2 billion worldwide in 2012 and has recently been studied for the treatment of heart failure.

Given the widespread interest in drug repurposing, the Roundtable on Translating Genomic-Based Research for Health of the Institute of Medicine hosted a workshop on June 24, 2013, in Washington, DC, to assess the current landscape of drug repurposing activities in industry, academia, and government. Stakeholders, including government officials, pharmaceutical company representatives, academic researchers, regulators, funders, and patients, were invited to present their perspectives and to participate in workshop discussions. Drug Repurposing and Repositioning is the summary of that workshop. This report examines enabling tools and technology for drug repurposing; evaluates the business models and economic incentives for pursuing a repurposing approach; and discusses how genomic and genetic research could be positioned to better enable a drug repurposing paradigm.

  1. ×

    Welcome to OpenBook!

    You're looking at OpenBook, NAP.edu's online reading room since 1999. Based on feedback from you, our users, we've made some improvements that make it easier than ever to read thousands of publications on our website.

    Do you want to take a quick tour of the OpenBook's features?

    No Thanks Take a Tour »
  2. ×

    Show this book's table of contents, where you can jump to any chapter by name.

    « Back Next »
  3. ×

    ...or use these buttons to go back to the previous chapter or skip to the next one.

    « Back Next »
  4. ×

    Jump up to the previous page or down to the next one. Also, you can type in a page number and press Enter to go directly to that page in the book.

    « Back Next »
  5. ×

    Switch between the Original Pages, where you can read the report as it appeared in print, and Text Pages for the web version, where you can highlight and search the text.

    « Back Next »
  6. ×

    To search the entire text of this book, type in your search term here and press Enter.

    « Back Next »
  7. ×

    Share a link to this book page on your preferred social network or via email.

    « Back Next »
  8. ×

    View our suggested citation for this chapter.

    « Back Next »
  9. ×

    Ready to take your reading offline? Click here to buy this book in print or download it as a free PDF, if available.

    « Back Next »
Stay Connected!